Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of AJU-R713 and R713R in Healthy Adults
NCT07231861Phase 1Completed
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pranlukast in asthma and perennial allergic rhinitis (PAR) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration. Started Dec 2025; status: completed.
02
Drugs
pranlukast
03
Conditions
asthmaperennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT07231861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231861.